Особенности экспрессии молекул-маркеров инсулинорезистентности при экспериментальной болезни Альцгеймера

Болезнь Альцгеймера (БА) характеризуется значительной потерей нейронов и синапсов, особенно в гиппокампе и коре больших полушарий мозга, внеклеточным накоплением β-амилоида и формированием нейрофибриллярных сплетений. Резистентность ЦНС к инсулину играет важную роль в развитии когнитивных нарушений и нейродегенерации. Однако клеточные и молекулярные механизмы связи инсулинорезистентности и БА остаются в значительной степени невыясненными. Большое значение имеет идентификация молекул-маркеров инсулинорезистентности, что, возможно, позволит сформировать новые подходы к направленной фармакологической коррекции нейродегенерации. Приведены данные об особенностях экспрессии IRAP, GLUT4 и IL-18 в различных областях головного мозга (гиппокамп, обонятельная луковица) у крыс с экспериментальной БА.

молекулы-маркеры, инсулинорезистентность, нейродегенерация, инсулинрегулируемая аминопептидаза

1. Prince M, Bryce R, Albanese E, et al. The global prevalence of dementia: A systematic review and metaanalysis.Alzheimer’s & Dementia. 2013;9(1):63-75.e62. doi: 10.1016/j.jalz.2012.11.007.

2. McKhann GM, Knopman DS, Chertkow H, et al. The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimer’s & Dementia. 2011;7(3):263-269. doi: 10.1016/j.jalz.2011.03.005.

3. Han W, Li C. Linking type 2 diabetes and Alzheimer’s disease. Proceedings of the National Academy of Sciences.2010;107(15):6557-6558. doi: 10.1073/pnas.1002555107.

4. Vos SJB, Verhey F, Frölich L, et al. Prevalence and prognosis of Alzheimer’s disease at the mild cognitive impairment stage. Brain. 2015;138(5):1327-1338. doi: 10.1093/brain/awv029.

5. Kim B, Feldman EL. Insulin resistance as a key link for the increased risk of cognitive impairment in the metabolic syndrome. Exp Mol Med. 2015;47(3):e149. doi: 10.1038/emm.2015.3.

6. Горина Я.В., Салмина А.Б., Кувачева Н.В., и др. Нейровоспаление и инсулинорезистентность при болезни Альцгеймера. // Сибирское медицинское обозрение. - 2014. - №4 - С. 11-19. [Gorina YV, Salmina AB, Kuvacheva NV, et al. Static mutations in the pathogenesis of spinocerebellar ataxias: from particular to general (Report III). Siberian medical review. 2014;(4):11-19. (In Russ.)]

7. Cai Z, Xiao M, Chang L, Yan L-J. Role of insulin resistance in Alzheimer’s disease. Metab Brain Dis.2014;30(4):839-851. doi: 10.1007/s11011-014-9631-3.

8. Liu C, Cui G, Zhu M, et al. Neuroinflammation in Alzheimer’s disease: chemokines produced by astrocytes and chemokine receptors. Int J Clin Exp Pathol. 2014;7(12):8342-8355.

9. Spielman LJ, Little JP, Klegeris A. Inflammation and insulin/IGF-1 resistance as the possible link between obesity and neurodegeneration. J Neuroimmunol. 2014;273(1-2):8-21. doi: 10.1016/j.jneuroim.2014.06.004.

10. Singhal G, Jaehne EJ, Corrigan F, et al. Inflammasomes in neuroinflammation and changes in brain function: a focused review. Front Neurosci. 2014;8. doi: 10.3389/fnins.2014.00315.

11. Zhang Q-Y, Pan Y, Wang R, et al. Quercetin inhibits AMPK/TXNIP activation and reduces inflammatory lesions to improve insulin signaling defect in the hypothalamus of high fructose-fed rats. The Journal of Nutritional Biochemistry.2014;25(4):420-428. doi: 10.1016/j.jnutbio.2013.11.014.

12. Chen Z, Zhong C. Decoding Alzheimer’s disease from perturbed cerebral glucose metabolism: Implications for diagnostic and therapeutic strategies. Prog Neurobiol. 2013;108:21-43. doi: 10.1016/j.pneurobio.2013.06.004.

13. Chai S, Yeatman HR, Parker MW, et al. Development of cognitive enhancers based on inhibition of insulin-regulated aminopeptidase. BMC Neurosci. 2008;9(Suppl 2):S14. doi: 10.1186/1471-2202-9-s2-s14.

14. Hermans SJ, Ascher DB, Hancock NC, et al. Crystal structure of human insulin-regulated aminopeptidase with specificity for cyclic peptides. Protein Sci. 2015;24(2):190-199. doi: 10.1002/pro.2604.

15. Yeatman H, Albiston A, Chai S. Insulin-regulated aminopeptidase in astrocytes: Role in Alzheimer’s disease? Alzheimer’s & Dementia. 2011;7(4):S668. doi: 10.1016/j.jalz.2011.05.1922.

16. Albiston AL, Yeatman HR, Pham V, et al. Distinct distribution of GLUT4 and insulin regulated aminopeptidase in the mouse kidney. Regul Pept. 2011;166(1-3):83-89. doi: 10.1016/j.regpep.2010.09.003.

17. Li X, Yuan H-f, Quan Q-k, et al. Scavenging effect of Naoerkang (???) on amyloid beta-peptide deposition in the hippocampus in a rat model of Alzheimer’s disease. Chin J Integr Med. 2011;17(11):847-853. doi: 10.1007/s11655-011-0896-7.

18. Sipos E, Kurunczi A, Kasza Á, et al. β-Amyloid pathology in the entorhinal cortex of rats induces memory deficits: Implications for Alzheimer’s disease. Neuroscience. 2007;147(1):28-36. doi: 10.1016/j.neuroscience.2007.04.011.

19. Encinas JM, Enikolopov G. Identifying and Quantitating Neural Stem and Progenitor Cells in the Adult Brain. 2008;85:243-272. doi: 10.1016/s0091-679x(08)85011-x.

20. Mabrouk RR, Mohamed HG, El-Kabarity RH. IL-18, An Indicator of Insulin Resistance? Proc Nutr Soc.2013;72(OCE1). doi: 10.1017/s0029665113000943.

21. Sutinen EM, Pirttilä T, Anderson G, et al. Pro-inflammatory interleukin-18 increases Alzheimer’s disease-associated amyloid-β production in human neuron-like cells. J Neuroinflammation. 2012;9(1):199. doi: 10.1186/1742-2094-9-199.

22. De La Monte SM. Insulin resistance and Alzheimer’s disease. BMB Reports. 2009;42(8):475-481. doi: 10.5483/BMBRep.2009.42.8.475.

23. Leguisamo NM, Lehnen AM, Machado UF, et al. GLUT4 content decreases along with insulin resistance and high levels of inflammatory markers in rats with metabolic syndrome. Cardiovasc Diabetol. 2012;11(1):100. doi: 10.1186/1475-2840-11-100.

24. Keller SR, Davis AC, Clairmont KB. Mice Deficient in the Insulin-regulated Membrane Aminopeptidase Show Substantial Decreases in Glucose Transporter GLUT4 Levels but Maintain Normal Glucose Homeostasis. J Biol Chem.2002;277(20):17677-17686. doi: 10.1074/jbc.M202037200.

25. Heneka M, Obanion M. Inflammatory processes in Alzheimer’s disease. J Neuroimmunol. 2007;184(1-2):69-91. doi: 10.1016/j.jneuroim.2006.11.017.

26. Wyss-Coray T, Rogers J. Inflammation in Alzheimer Disease--A Brief Review of the Basic Science and Clinical Literature. Cold Spring Harb Perspect Med. 2011;2(1):a006346-a006346. doi: 10.1101/cshperspect.a006346.

27. Griffin WST. Neuroinflammatory Cytokine Signaling and Alzheimer’s Disease. N Engl J Med. 2013;368(8):770-771. doi: 10.1056/NEJMcibr1214546.

28. Griffin RJ, Moloney A, Kelliher M, et al. Activation of Akt/PKB, increased phosphorylation of Akt substrates and loss and altered distribution of Akt and PTEN are features of Alzheimer’s disease pathology. J Neurochem. 2005;93(1):105-117. doi: 10.1111/j.1471-4159.2004.02949.x.

29. Ojala J, Alafuzoff I, Herukka S-K, et al. Expression of interleukin-18 is increased in the brains of Alzheimer’s disease patients. Neurobiol Aging. 2009;30(2):198-209. doi: 10.1016/j.neurobiolaging.2007.06.006.

30. Ojala JO, Sutinen EM, Salminen A, Pirttilä T. Interleukin-18 increases expression of kinases involved in tau phosphorylation in SH-SY5Y neuroblastoma cells. J Neuroimmunol. 2008;205(1-2):86-93. doi: 10.1016/j.jneuroim.2008.09.012.

31. Pickering M, O’Connor JJ. Pro-inflammatory cytokines and their effects in the dentate gyrus. 2007;163:339-354. doi: 10.1016/s0079-6123(07)63020-9.

32. Teune L, Strijkert F, Renken R, et al. The Alzheimer’s Disease-Related Glucose Metabolic Brain Pattern. Curr Alzheimer Res. 2014;11(8):725-732. doi: 10.2174/156720501108140910114230.

33. Emmanuel Y, Cochlin LE, Tyler DJ, et al. Human hippocampal energy metabolism is impaired during cognitive activity in a lipid infusion model of insulin resistance. Brain and Behavior.2013;3(2):134-144. doi: 10.1002/brb3.124.

34. Albiston AL, Diwakarla S, Fernando RN, et al. Identification and development of specific inhibitors for insulin-regulated aminopeptidase as a new class of cognitive enhancers. Br J Pharmacol. 2011;164(1):37-47. doi: 10.1111/j.1476-5381.2011.01402.x.

35. Fernando RN, Larm J, Albiston AL, Chai SY. Distribution and cellular localization of insulin-regulated aminopeptidase in the rat central nervous system. The Journal of Comparative Neurology. 2005;487(4):372-390. doi: 10.1002/cne.20585.

36. Fernando RN, Albiston AL, Chai SY. The insulin-regulated aminopeptidase IRAP is colocalised with GLUT4 in the mouse hippocampus - potential role in modulation of glucose uptake in neurones? Eur J Neurosci. 2008;28(3):588-598. doi: 10.1111/j.1460-9568.2008.06347.x.

37. Yeh T-Yin J, Sbodio Juan I, Tsun Z-Y, et al. Insulin-stimulated exocytosis of GLUT4 is enhanced by IRAP and its partner tankyrase. Biochem J. 2007;402(2):279-290. doi: 10.1042/bj20060793.

38. Keller SR. The insulin-regulated aminopeptidase: a companion and regulator of GLUT4. Front Biosci. 2003;8(1-3):s410. doi: 10.2741/1078.

39. Stockli J, Fazakerley DJ, James DE. GLUT4 exocytosis. J Cell Sci. 2012;124(24):4147-4159. doi: 10.1242/jcs.097063.

40. Lim C-Y, Bi X, Wu D, et al. Tropomodulin3 is a novel Akt2 effector regulating insulin-stimulated GLUT4 exocytosis through cortical actin remodeling. Nature Communications. 2015;6:5951. doi: 10.1038/ncomms6951.